Brian Corvese - 01 Dec 2022 Form 4 Insider Report for MiNK Therapeutics, Inc. (INKT)

Reporting relationship: Director
Issuer ticker: INKT
Reported as of: 01 Dec 2022
Net transaction value: +$17,876
SEC form: 4
Accepted by SEC: 05 Dec 2022, 16:20:28 UTC
Prior SEC filing: 19 Sep 2022
Next SEC filing: 03 Mar 2023
Source filing: View source filing
Reporting owner signature: By: /s/ Christine Klaskin, Attorney-in-Fact

Key filing fact

Brian Corvese filed Form 4 for MiNK Therapeutics, Inc. (INKT) on 05 Dec 2022.

Key facts

This page summarizes Brian Corvese's Form 4 filing for MiNK Therapeutics, Inc. (INKT).
1 reported transaction and 0 derivative rows are listed below.
Accepted by SEC: 05 Dec 2022, 16:20.

Change

Previous filing in this sequence was filed on 19 Sep 2022.
Current net transaction value: +$17,876.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

INKT transaction

Common Stock

Award

Transaction value: $17,876
Shares: +6,849
Change %: +2.3%
Price: $2.61
Shares after: 298,795
Date: 01 Dec 2022
Ownership: Direct
Footnotes: F1, F2

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 2 footnotes

Footnote F1

The Reporting Person was granted restricted stock units ("RSUs"), which represent a contingent right to receive one share of Common Stock for each RSU. The RSUs were received in lieu of cash retainers for board and committee compensation. The RSUs will vest one month from the grant date.

Footnote F2

Amount owned includes 278,300 shares that were inadvertently excluded from a Form 4 filed on September 19, 2022.